ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 122

A Small Number of Patients with SLE Account for Most of the Direct and Indirect Hospitalization Costs

Allen P. Anandarajah1, Bethany A. Marston2, Debbie Campbell3 and Christopher T. Ritchlin4, 1Dept of Rheumatology, Univ of Rochester Med Ctr, Rochester, NY, 2Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, 3Allergy, Immunology & Rheumatology, University of Rochester, Rochester, NY, 4Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: cost containment and high risk, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Healthcare Disparities in Rheumatology - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that can affect multiple organ systems and is associated with high morbidity. Studies have shown that there is a substantial health care costs associated with hospitalization of SLE patients. Among chronic, complex disease, often a small percentage of patients account for the majority of health care spending. Objective: To identify if there is a high risk, high cost group of SLE patients among all hospital admissions for SLE over a 2 year period.

Methods:  We conducted a financial analysis of all admissions for systemic lupus erythematosus at the Strong Memorial Hospital between the July 1st of 2013 and June 30thof 2015. The total number of admissions for diagnosis code 710.0 was calculated based on primary or secondary diagnosis for the 2 fiscal years. The diagnosis of SLE was confirmed based on the presence of at least 4 criteria or had to be made by a rheumatologist. The age at time of admission and age when diagnosis of SLE was first made, gender, race, reason for admission and the zip code of the primary residence were recorded. Additionally, we noted the number of readmissions within a year and readmission within a 30-day period. We then determined the total cost of admissions, readmission and recorded the length of stay for all admissions and readmissions.

Results:  The total number of confirmed cases of SLE admissions for the 2 years was 387 that comprised 202 patients. Of these 175 (45%) were due to readmissions (within a year) and 113 (29%) were readmissions within a 30 day period. The total cost of all admissions was $10,353,617 for the 2 years while the cost of readmissions was $1,772,675.00 per year. The cost of all readmissions within the 30-day period was $1,182,375 for the 2 year period. The length of stay for all SLE admissions was 1,564 days per year. Approximately, 44% of admitted patients were of American origin with 60% residing within the city of Rochester.Further analysis showed that 28 (16%) of the patients accounted for about 40% of the total cost of all admissions ($3,900,156), 45% of the length of stay, 49% of all admissions and 76% of all 30-day readmissions. These high risk patients were more likely to be younger, have earlier onset of SLE, more likely to be African American and more likely to be from within the city limits. The average cost of hospitalization for the high risk patients was $150,000 compared to $51,808 for other SLE patients. See Table

Conclusion:  Hospitalizations of patients with SLE is a major cause for health care costs and readmission rates for SLE are high. A small group of high risk, high cost patient’s account for majority of the hospitalization costs and length of stay among all SLE patient hospitalizations. A high-riskcare management plan could substantially reduce costs and improve quality of care for these patients.  

  High risk SLE patient SLE patient
Average cost/patient/YEAR $ 150,000.06 $ 51,808.41
Average LOS/patient 48.3 days 15.6 days
     
Mean age (at admission) 38.2 years 45.5 years
Mean age (at initial diagnosis) 20 years 30.2 years
AA: C: A: H 61%: 29%: 7%: 3% 44%: 49%: 2%: 4%
     
Females: Males 82%:18% 91%:9%
Rochester zip code 75% 60%

AA: African American; C: Caucasian; A: Asian; H: Hispanic; LOS-length of stay


Disclosure: A. P. Anandarajah, None; B. A. Marston, None; D. Campbell, None; C. T. Ritchlin, Amgen, Janssen Pharmaceutica Product, L.P., and UCB, 2,AbbVie, Amgen, Janssen Pharmaceutica Product, L.P., Regeneron, and UCB, 5.

To cite this abstract in AMA style:

Anandarajah AP, Marston BA, Campbell D, Ritchlin CT. A Small Number of Patients with SLE Account for Most of the Direct and Indirect Hospitalization Costs [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/a-small-number-of-patients-with-sle-account-for-most-of-the-direct-and-indirect-hospitalization-costs/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-small-number-of-patients-with-sle-account-for-most-of-the-direct-and-indirect-hospitalization-costs/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology